Overview of Novel Antipsychotic Drugs: State of the Art, New Mechanisms, and Clinical Aspects of Promising Compounds
Open Access
- 1 January 2025
- journal article
- review article
- Published by MDPI AG in Biomedicines
- Vol. 13 (1) , 85
Abstract
Antipsychotic medications are a vast class of drugs used for the treatment of psychotic disorders such as schizophrenia. Although numerous compounds have been developed since their introduction in the 1950s, several patients do not adequately respond to current treatments, or they develop adverse reactions that cause treatment discontinuation. Moreover, in the past few decades, discoveries in the pathophysiology of psychotic disorders have opened the way for experimenting with novel compounds that have alternative mechanisms of action, with some of them showing promising results in early trials. The scope of this review was to summarize the novel antipsychotics developed, their current experimental status, and their mechanisms of action. In particular, we analyzed the main classes of investigational antipsychotics, such as monoamine, glutamate, acetylcholine, cannabinoid receptor modulators, enzyme inhibitors, ion channel modulators, and mixed receptor modulators. In addition, the safety profiles and adverse effects of these drugs were carefully evaluated, considering the relevance of these aspects for patients’ drug adherence and quality of life, especially in the long-term treatment. Lastly, we tried to understand which compounds have greater potential to be approved by the principal drug regulatory agencies in the next years and if they could be used for diseases other than psychotic disorders.Keywords
This publication has 123 references indexed in Scilit:
- Evidence of trospium’s ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study resultsPsychopharmacology, 2023
- Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophreniaEuropean Archives of Psychiatry and Clinical Neuroscience, 2023
- Potential beneficial effects of masupirdine (SUVN‐502) on agitation/aggression and psychosis in patients with moderate Alzheimer's disease: Exploratory post hoc analysesInternational Journal of Geriatric Psychiatry, 2022
- A randomized, double-blind, placebo controlled, phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of LB-102, a selective dopamine D2/3/5-HT7 inhibitorPsychopharmacology, 2022
- Population pharmacokinetic analysis of ulotaront in subjects with schizophreniaCPT: Pharmacometrics & Systems Pharmacology, 2021
- Maintenance treatment with antipsychotic drugs for schizophreniaCochrane Database of Systematic Reviews, 2020
- Preclinical disposition of MGS0274 besylate, a prodrug of a potent group II metabotropic glutamate receptor agonist MGS0008 for the treatment of schizophreniaPharmacology Research & Perspectives, 2019
- The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trialPsychopharmacology, 2018
- Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's diseaseDrug Development Research, 1997
- Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor bindingPsychopharmacology, 1996